An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein—short review

Sahana Pai, Jayesh Mudgal, B. Venkatesh Kamath, K. Sreedhara Ranganath Pai

Research output: Contribution to journalReview articlepeer-review

Abstract

Human immunodeficiency virus-1 (HIV-1) infection remains to be one of the major threats throughout the world. Many researchers are working in this area to find a cure for HIV-1. The group of the FDA approved drugs which are currently used against HIV-1 in the clinical practice include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors (InIs), and protease inhibitors (PIs). Fixed dose combinations (FDCs) of these drugs are available and are used as per the anti-retroviral therapy (ART) guidelines. Despite these, unfortunately, there is no cure for HIV1 infection to date. The present review is focused upon describing the importance of a post-transcriptional regulatory protein “Rev”, responsible for latent HIV-1 infection as a possible, and promising therapeutic target against HIV-1.

Original languageEnglish
JournalPharmacological Reports
DOIs
Publication statusAccepted/In press - 2021

All Science Journal Classification (ASJC) codes

  • Pharmacology

Fingerprint Dive into the research topics of 'An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein—short review'. Together they form a unique fingerprint.

Cite this